Table 1.
Multivariate analysis of overall survival (OS) or disease specific survival (DSS) in the second cohort (n = 188) after treatment
| Characteristics | Hazards ratio (OS) (95% confidence interval) | p-value (OS) | Hazards ratio (DSS) (95% confidence interval) | p-value (DSS) |
|---|---|---|---|---|
| Age (median: 50.6) | ||||
| < 50.6y | 1.000 (Reference) | 0.321 | 1.000 (Reference) | 0.384 |
| > 50.6y | 1.351 (0.745–2.451) | 1.342 (0.692–2.602) | ||
| Gender | ||||
| Male | 1.000 (Reference) | 0.459 | 1.000 (Reference) | 0.206 |
| Female | 0.685 (0.252–1.864) | 0.517 (0.186–1.440) | ||
| Overall pathological stage | ||||
| I–II | 1.000 (Reference) | 0.022a | 1.000 (Reference) | 0.079 |
| III–IV | 3.128 (1.172–8.344) | 2.460 (0.900–6.723) | ||
| Perineural invasion | ||||
| No | 1.000 (Reference) | 0.058 | 1.000 (Reference) | 0.018a |
| Yes | 1.823 (0.979–3.395) | 2.329 (1.150–4.716) | ||
| Cell differentiation b | ||||
| W-D + M-D P-D | 1.000 (Reference) | 0.935 | 1.000 (Reference) | 0.750 |
| 1.035 (0.456–2.348) | 0.857 (0.332–2.215) | |||
| Bone invasion | ||||
| No | 1.000 (Reference) | 0.901 | 1.000 (Reference) | 0.634 |
| Yes | 1.042 (0.543–1.999) | 0.831 (0.389–1.779) | ||
| APOBEC3A expression level | ||||
| Low | 1.000 (Reference) | 0.035a | 1.000 (Reference) | 0.028a |
| High | 0.499 (0.261–0.954) | 0.444 (0.215–0.917) | ||
Multivariate analyses also adjusted with patients’ age and sex
astatistically significant
bW-D: well-differentiated, M-D: moderately-differentiated, and P-D: poorly-differentiated, squamous cell carcinoma